Please find enclosed herewith the newspaper advertisement for the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended 31/December/2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries has published its Q3 FY26 (quarter ended 31 December 2025) and nine-month unaudited results in newspapers Mumbai Lakshdeep and Financial Express, as required under listing rules. On a consolidated basis, revenue from operations for the quarter stood at around ₹16,867 lakhs versus ₹15,801 lakhs in the year-ago quarter, a growth of roughly 7%. For the nine months ended December 2025, consolidated revenue jumped to about ₹50,504 lakhs versus ₹34,344 lakhs in the same period last year, a strong ~47% jump. Consolidated net profit for the quarter was about ₹174 lakhs (vs ₹143 lakhs YoY), while nine-month net profit rose to about ₹502 lakhs versus ₹306 lakhs last year. Basic EPS for the quarter was ₹0.62 and for nine months was ₹2.30, compared to ₹0.50 and ₹1.34 respectively a year earlier.
Healthy revenue and profit growth on a year-on-year basis, with the nine-month performance nearly doubling profits, which is a positive signal for shareholders. The filing itself is a routine regulatory compliance disclosure and is unlikely to move the stock on its own, but the strong underlying numbers may support investor sentiment.